Delivering precision medicine to thousands of Australians with advanced, incurable and early-onset cancers.

Through cutting edge genomics and innovative clinical trials research, we’re connecting Australia’s leading specialists, researchers, industry partners and patients in the spirit of one common goal: outsmarting cancer, together.

MoST Clinical Trials

Molecular Screening & Therapeutics (MoST) Study

MoST is a research study that uses the power of genomic technologies to identify new potential drug targets, characterise molecular changes in a patient's cancer, and to bring those drugs to patients in the form of clinical trials.

Patient pathway

Is my patient eligible for the molecular screening program?

If you answer “yes” to the following statements your patient may qualify for the pan cancer and leukaemia/lymphoma cohorts.

Your patient:

  • is aged 18 years and older, with pathologically confirmed advanced and/or metastatic cancer of any histologic type, including haematological cancers, or an earlier diagnosis of a poor prognosis cancer;
  • has tissue available for molecular screening;
  • has no more than one standard treatment available.
  • is self-caring in all activities of daily living, and out of bed more than half of each day (ECOG performance status 0, 1 or 2).
  • is not pregnant, lactating or planning to become pregnant.


If you answer “yes” to the following statements your patient may qualify for the lung cancer cohort.

Your patient:

  • is aged 18 years and older, with newly diagnosed pathologically confirmed metastatic non-squamous non-small cell lung cancer (mNSCLC);
  • has tissue available for molecular screening;
  • has an ECOG performance status 0 or 1.
  • has not had any previous treatment for metastatic non-squamous NSCLC.

How do I get my patient onto the MoST program?

To get your patient onto the molecular screening stage of the program you will need to:

  • Contact us or complete the MoST referral form (see the link below); for ASPiRATION follow the link above
  • Supply a histopathology report for your patient and any relevant clinical information
  • Receive the results of molecular screening test and discuss the results with your patient
  • If appropriate and available, refer your patient to a MoST clinical trial or follow up on treatment options highlighted in the screening report
  • Continue to provide us with follow up information about your patient.
MoST Program referral form

What will MoST do?

If your patient is eligible for the screening program we will:

  • Consent your patient into the screening study
  • Arrange to access tumour tissue held by a pathology centre
  • Arrange for collection of a blood sample
  • Analyse the tissue (molecular profiling)
  • Following review by our molecular tumour board (MTB), provide you with a report containing the tumour molecular profile of the tumour and therapeutic recommendations including clinical trials.

Resources and patient support

The Australian Rare Cancer (ARC) Portal is an online referral service that aims to improve outcomes and access to research for Australians diagnosed with a rare cancer.

The ARC Portal offers expert clinical advice, particularly for Australians who live outside the major cancer treatment centres in metropolitan areas.

visit the ARC portal

Rare Cancer Australia (RCA) provides support and advocacy for patients.

visit the RCA website

Canteen can provide support and someone to talk to for patients aged 12 – 25.

visit the Canteen website

Contact us for more information

For more information, please email or or call (02) 9355 5874.


Early detection and inherited cancer risk (RisC and SMOC+) studies

Understanding the genetic variants that cause inherited cancer and developing new surveillance strategies to enable early cancer detection in those at highest risk.

How the RisC and SMOC+ programs work

Can my patient participate in RisC or SMOC+?

The RisC study is open to patients diagnosed with a cancer less than 40 years of age, patients diagnosed with 2 different cancer less than 50 years of age or 3 or more cancers over the age of 50 years.

SMOC+ is open to individuals at high risk of cancer due to their inherited genetic make-up. A referral from a family cancer clinic or genetic research study is required.

What does RisC participation mean to your patient?

On referral, the RisC team  will send study information to the patient and discuss the details, by telephone or face to face. Participation will involve:

  • consent for RisC to access medical and similar records, as well as samples held by pathology centres
  • donation of  a blood sample
  • providing a family history
  • completion of a series of questionnaires
  • optional consent for sample biobanking.
  • optional consent for access to Medicare/PBS data

What does SMOC+ participation involve for your patient?

On referral, the SMOC+ team  will send out study information to the patient. Participation will involve:

  • consenting for SMOC+ to access medical records
  • visiting a family cancer clinic annually for a physical examination
  • donating an annual blood sample
  • completion of a series of questionnaires
  • optional consent for access to Medicare/PBS data
  • annual whole body MRI
  • other surveillance according to the protocol.

What will RisC do?

RiSC  will perform a whole genome sequence to understand more about the genetic variants that might contribute to a risk of inherited cancer.

Contact us for more information

For more information, please email or call (02) 9355 5761.

Our Network

Omico is a nationwide network of research and treatment centres that facilitate, support and promote genomic cancer medicine.

Find a site near you

Australian Rare Cancer (ARC) Portal

Referring patients to the Australian Rare Cancer portal gives streamlined access to expert opinion and advice on management and treatment options.

Read more